JP Morgan Chase
PLRX icon

JP Morgan Chase’s Pliant Therapeutics PLRX Stock Holding History

JP Morgan Chase’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200,200
Closed -$5.33M – 7243
2023
Q1 		$5.33M Buy
+200,200
New +$5.7M ﹤0.01% 2767

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

JP Morgan Chase's PLRX Position: Q2 2026 in Review

JP Morgan Chase reduced its Pliant Therapeutics (PLRX) stake by 21% in Q2 2026, selling an estimated $219K and leaving 681,647 shares worth $784K. The position accounts for ﹤0.01% of the portfolio, ranked #4841.

JP Morgan Chase first reported a position in PLRX in Q3 2020 and has held it in 24 quarters since. The position peaked at $3.15M in Q3 2025. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • JP Morgan Chase held 681,647 shares of Pliant Therapeutics worth $784K as of Q2 2026.
  • JP Morgan Chase sold 180,176 Pliant Therapeutics shares in Q2 2026, an estimated $219K.
  • Pliant Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4841 holding.
  • JP Morgan Chase first reported a position in Pliant Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Pliant Therapeutics position peaked at $3.15M in Q3 2025.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.